Abstract
Background
Management of mammographically detected ductal carcinoma in situ (DCIS) at a single institution was reviewed to determine long-term clinical outcomes after treatment with breast-conserving therapy (BCT).
Methods
Data from all patient-cases with DCIS who received BCT between 1980 and 1993 were reviewed. Patient demographics and pathologic factors were analyzed for their effect on outcomes, including ipsilateral breast tumor recurrence (IBTR) and survival. BCT included breast-conserving surgery followed by external-beam radiotherapy to the whole breast, with 86 % of patients receiving a lumpectomy cavity boost. The median dose to the whole breast was 50 Gy and 60.4 Gy to the lumpectomy cavity.
Results
A total of 129 cases were evaluated; the median follow-up was 19.3 years. Twenty-one patients developed an ipsilateral breast tumor recurrence (IBTR), 76.2 % of which were invasive (n = 16). Fourteen recurrences (66 %) were within the same breast quadrant (true recurrence), while an additional 7 cases developed an IBTR elsewhere in the breast. True recurrences were more prevalent in women <45 years of age (20 %/24 % vs. 5.1 %/8 %) at 10 and 20 years (p = 0.02). The 5-, 10-, 15-, and 20-year actuarial rates of IBTR for this cohort were 8.7, 10.4, 12.1, and 16.3 % (IBTR), while overall survival at 5, 10, and 20 years was 97.6, 96.8, and 96.8 %, respectively.
Conclusions
Mammographically detected DCIS remains a clinically distinct subset of noninvasive breast cancer. With 20 year follow-up, local control and overall survival are excellent after BCT.
Similar content being viewed by others
References
Lagios MD. Duct carcinoma in situ. Surg Clin North Am. 1990;4:853–71.
Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913–8.
Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010:139–41.
Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 2005;103:1778–84.
Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–88.
Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853. J Clin Oncol. 2006;24:3381–7.
Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21–9.
Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26:1247–52.
Motwani SB, Goyal S, Moran MS, et al. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG study 5194. Cancer. 2011;117:1156–62.
Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010:162–77.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.
Bornstein BA, Recht A, Connolly JL, et al. Results of treating ductal carcinoma in situ of the breast with conservative surgery and radiation therapy. Cancer. 1991;67:7–13.
Forquet A, Zafrani B, Compana F, et al. Breast-conserving treatment of ductal carcinoma in situ. Semin Radiat Oncol. 1992;2:116–24.
McCormick B, Rosen PO, Kinne D, et al. Duct carcinoma in situ of the breast: an analysis of local control and conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 1991;21:289–92.
Solin LJ, Fowble BL, Schultz DI, et al. Definitive irradiation for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1990;19:843–50.
White J, Levine A, Gustafson G, et al. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma-in situ of the breast treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1995;31:791–7.
Kestin LL, Goldstein NS, Lacerna MD, et al. Factors associated with local recurrence of mammographically detected dunctal carcinoma in situ in patients given breast-conserving therapy. Cancer. 2000;88:596–607.
Vicini FA, Lacerna MD, Goldstein NS, et al. Ductal carcinoma in situ detected in the mammographic era: an analysis of clinical, pathologic, and treatment-related factors affecting outcome with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 1997;39:627–35.
Soli LJ, Kurtz J, Forquet A, et al. Fifiteen-year results of breast conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14:754–63.
Fowble B, Hanlon AL, Fein DA, et al. Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS). Int J Radiat Oncol Biol Phys. 1997;38:949–57.
Recht A, Silver B, Schnitt S, et al. Breast relapse following primary radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys. 1985;11:1271–6.
Stomper PC, Connolly JL, Meyer JE, et al. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic–pathologic correlation. Radiology. 1989;172:235–41.
Walker RA, Dearing SJ, Brown LA. Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast. Hum Pathol. 1999;30:943–8.
Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys. 2002;53:687–91.
Chadha M, Mehta P, Feldman S, et al. Intraoperative high-dose-rate brachytherapy—a novel technique in the surgical management of axillary recurrence. Breast J. 2009;15:140–5.
Trombetta M, Julian TB, Werts ED, et al. Comparison of conservative management techniques in the re-treatment of ipsilateral breast tumor recurrence. Brachytherapy. 2011;10:74–80.
Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24:1031–6.
Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319–24.
Goyal S, Vicini F, Beitsch PD, et al. Ductal carcinoma in situ treated with breast-conserving surgery and accelerated partial breast irradiation: comparison of the Mammosite registry trial with Intergroup Study E5194. Cancer. 2011;117:1149–55.
Holland R, Hendriks JH. Microcalcifications associated with ductal carcinoma in situ: mammographic–pathologic correlation. Semin Diagn Pathol. 1994;11:181–92.
Shaitelman SF, Grills IS, Kestin LL, et al. Rates of second malignancies after definitive local treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2011;81:1244–51.
Schwartz GF, Finkel GC, Garcia JC, et al. Subclinical ductal carcinoma in situ of the breast: treatment by local excision and surveillance alone. Cancer. 1992;70:2468–74.
Disclosure
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wilkinson, J.B., Vicini, F.A., Shah, C. et al. Twenty-Year Outcomes after Breast-Conserving Surgery and Definitive Radiotherapy for Mammographically Detected Ductal Carcinoma In Situ. Ann Surg Oncol 19, 3785–3791 (2012). https://doi.org/10.1245/s10434-012-2412-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-012-2412-5